India's Gland Pharma surges after FDA concludes Hyderabad facility inspection
24/11/2023 05:23
** Shares of generic injectables maker Gland Pharma
GLAD.NS rise as much as 6.4% to 1,817.7 rupees, highest since
Nov 30, 2022
** GLAD says it received Establishment Inspection Report
from U.S. FDA, indicating inspection at its Pashamylaram
facility in Hyderabad from Aug 23-26 has closed
** Stock last up 5.6%, taking YTD gains to 14.4%; Nifty
Pharma .NIPHARM up 27% YTD
** Trading volumes up sharply, more than 2x vs 30-day avg
(Reporting by Chris Thomas)
((chris.thomas@thomsonreuters.com; +91-80-6749-8695; Reuters
Messaging: chris.thomas.thomsonreuters.com@reuters.net))
Recent news on Gland Pharma
See all newsIndia Stocks: Indian shares open higher as Fed-hike fears, oil prices ease; financials lead
India Stocks: Indian shares poised to rebound as Fed-hike fears, oil prices ease
Brief: Gland Pharma Approves $21 Million Investment In Gland Pharma Usa
Brief: Fosun Pharma Says Unit Sold Gland Pharma Shares for $294 Mln
India's Gland Pharma gains on successful completion of US FDA probe at Visakhapatnam plant